Antipsychotics,the heartland of clinical psychopharmacology?

Abstract

Get full access to this article

View all access options for this article.

References

Avrahami

Peskin

Moore

, et al. (2021) Body mass index increase in preschoolers with heterogeneous psychiatric diagnoses treated with risperidone. J Psychopharmacol. Epub ahead of print 23 April 2021. DOI: 10.1177/02698811211008592

Béchard

Corbeil

Plante

, et al. (2021) Clozapine rechallenge following neutropenia using granulocyte colony-stimulating factor: A Quebec case series. J Psychopharmacol. Epub ahead of print 6 July 2021. DOI: 10.1177/02698811211029737

Besag

Vasey

Lao

, et al. (2021) Pharmacological treatment for Tourette syndrome in children and adults: What is the quality of the evidence? A systematic review. J Psychopharmacol. Epub ahead of print 21 July 2021. DOI: 10.1177/02698811211032445

Costardi

Gadelha

Bressan

(2021) Individualizing tapering antipsychotic schemes considering D2 blockade dynamics. J Psychopharmacol. Epub ahead of print 27 July 2021. DOI: 10.1177/02698811211000780

de Filippis

Soldevila-Matías

Guinart

, et al. (2021) Unravelling cases of clozapine-related drug reaction with eosinophilia and systemic symptoms (DRESS) in patients reported otherwise: A systematic review. J Psychopharmacol. Epub ahead of print 27 May 2021. DOI: 10.1177/02698811211021587

Delay

Deniker

Harl

(1952) [Therapeutic method derived from hiberno-therapy in excitation and agitation states]. Ann Med Psychol 110: 267–273.

Ebert

Bär

K-J

(2010) Emil Kraepelin: A pioneer of scientific understanding of psychiatry and psychopharmacology. Indian J Psychiatry 52: 191–192.

Forte

Pompili

Imbastaro

, et al. (2021) Effects on suicidal risk: Comparison of clozapine to other newer medicines indicated to treat schizophrenia or bipolar disorder. J Psychopharmacol. Epub ahead of print 22 July 2021. DOI: 10.1177/02698811211029738

Goodwin

Geddes

(2007) What is the heartland of psychiatry? Br J Psychiatry 191: 189–191.

10.

Hommers

Scherf-Clavel

Stempel

, et al. (2021) Antipsychotics in routine treatment are minor contributors to QT prolongation compared to genetics and age. J Psychopharmacol. Epub ahead of print 28 March 2021. DOI: 10.1177/02698811211003477

11.

Jauhar

Young

(2019) Controversies in bipolar disorder; role of second-generation antipsychotic for maintenance therapy. Int J Bipolar Disord 7: 10.

12.

Kalk

Young

(2017) Footnotes to Kraepelin: changes in the classification of mood disorders with DSM-5. BJPsych open 3: e1–e3.

13.

Kapur

(2000) Relationship between dopamine D2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. Am J Psychiatr 157: 514–520.

14.

Kølbæk

Dines

Holm

, et al. (2021) Clinical validation of ratings on the six-item Positive and Negative Syndrome Scale obtained via the Simplified Negative and Positive Symptoms Interview. J Psychopharmacol. Epub ahead of print 28 March 2021. DOI: 10.1177/0269881121996890

15.

Livingston

Hawkins

Gilleen

, et al. (2021) Preliminary evidence for the phosphodiesterase type-4 inhibitor, roflumilast, in ameliorating cognitive flexibility deficits in patients with schizophrenia. J Psychopharmacol. Epub ahead of print 28 April 2021. DOI: 10.1177/02698811211000778

16.

McAllister-Williams

(2008) Do antidepressants work? A commentary on “Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration” by Kirsch et al. Evid Based Ment Health 11: 66–68.

17.

Meighan

Elston

Bilkey

, et al. (2021) Impaired discrimination of a subanesthetic dose of ketamine in a maternal immune activation model of schizophrenia risk. J Psychopharmacol. DOI: 10.1177/02698811211029739

18.

Onen

Taymur

(2021) Evidence for the atherogenic index of plasma as a potential biomarker for cardiovascular disease in schizophrenia. J Psychopharmacol. Epub ahead of print 26 June 2021. DOI: 10.1177/02698811211026450

19.

Papanastasiou

Shergill

(2021) Why should pharmacological trials in schizophrenia employ functional magnetic resonance imaging (fMRI)? J Psychopharmacol. Epub ahead of print 28 April 2021. DOI: 10.1177/02698811211000773

20.

Rafeyan

Papakostas

Jackson

, et al. (2020) Inadequate response to treatment in major depressive disorder: Augmentation and adjunctive strategies. J Clin Psychiatry 81: OT19037BR3.

21.

Reynolds

(2021) High dose antipsychotic polypharmacy and dopamine partial agonists: Time to rethink guidelines? J Psychopharmacol. Epub ahead of print 14 July 2021. DOI: 10.1177/02698811211026456

22.

Wallman

Clark

Taylor

(2021) Discontinuation and relapse with paliperidone palmitate three-monthly for maintenance of schizophrenia: Two year follow-up of use in clinical practice. J Psychopharmacol. Epub ahead of print 28 April 2021. DOI: 10.1177/02698811211009794

23.

Wang

Han

Lee

, et al. (2016) Second generation antipsychotics in the treatment of major depressive disorder: An update. Chonnam Med J 52: 159–172. Erratum in: Chonnam Med J. 2019; 55: 73.

24.

Wang

Cheng

, et al. (2021) Efficacy and tolerability of pharmacological interventions on metabolic disturbance induced by atypical antipsychotics in adults: A systematic review and network meta-analysis. J Psychopharmacol. Epub ahead of print 27 July 2021. DOI: 10.1177/02698811211035391

25.

Young

Moulton

(2020) Antidepressants do work after all. J Psychopharmacol 34: 1071–1073.

26.

Zarate

Jr Tohen

Banov

, et al. (1995) Is clozapine a mood stabilizer? J Clin Psychiatry 56: 108–112.